Lineage Cell Therapeutics Inc. presented results from the company's imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA).
Lineage Cell Therapeutics Inc. presented results from the company's imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA). (Image Credit: Adobe Stock/mik_cz)
Lineage Cell Therapeutics Inc. presented results at the 2023 ARVO annual meeting from the imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), which is development as a potential treatment for geographic atrophy (GA).
The presentation, “Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial” was presented by Eyal Banin, MD, PhD, director of the Center for Retinal and Macular Degenerations, Department of Ophthalmology at Hadassah-Hebrew University Medical Center, on behalf of Roche and Genentech.
According to the company, RG6501 is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It is being developed under an exclusive global collaboration between Lineage, Roche and Genentech, and is currently being evaluated in a Phase 2a clinical study (NCT05626114) in patients with GA secondary to AMD.
Brian Culley, CEO of Lineage, pointed out the company was pleased to see its observations of improved retinal structure in the initial clinical study of OpRegen are being reinforced by additional external and independent analyses of the images performed by Genentech and Roche.
“Looking ahead, we are excited to collaborate with Genentech and Roche on the ongoing Phase 2a study of OpRegen, which is currently enrolling patients and open at multiple sites in the US, with more sites expected to come online this year,” Culley said.
“I have been closely involved with the OpRegen program since its beginning and I continue to be excited about the potential therapeutic benefit for patients afflicted with dry AMD and geographic atrophy, a progressive and debilitating disease that significantly affects the quality of life of many,” Banin said. “These data further highlight the potential for a single dose of OpRegen to provide significant clinical outcomes for patients in a disease with a tremendous unmet need.”
ARVO presentation highlights